Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies

Cardiovascular Research

Volumn 74, Issue 3, 2007, Pages 343-355

  Dirksen, Maurits T ^a   Laarman, Gerrit J ^a   Simoons, Maarten L ^b   Duncker, Dirk J G M ^b  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute myocardial infarction; Clinical; Experimental; Reperfusion; Reperfusion injury; Review

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; CARIPORIDE; CLOPIDOGREL; DILTIAZEM; DOBUTAMINE; ENALAPRILAT; ENIPORIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FLUOSOL; GLUCOSE; GLYCERYL TRINITRATE; HEPARIN; INSULIN; LIDOCAINE; MAGNESIUM; MAGNESIUM SULFATE; NICORANDIL; NITROPRUSSIDE SODIUM; NORPHENAZONE; OPIATE; PEXELIZUMAB; PLACEBO; POLOXAMER; POTASSIUM; TRIMETAZIDINE; UNINDEXED DRUG; VASODILATOR AGENT;

ADD ON THERAPY; CARDIOVASCULAR RISK; CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; EXPERIMENTAL MODEL; EXPERIMENTAL STUDY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE INJURY; HEART MUSCLE REPERFUSION; HUMAN; ISCHEMIC PRECONDITIONING; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPERFUSION INJURY; REVIEW; THROMBUS;

ADENOSINE; ANTIOXIDANTS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; CORONARY DISEASE; FORECASTING; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; SODIUM-HYDROGEN ANTIPORTER; TREATMENT OUTCOME;

EID: 34247859379     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2007.01.014     Document Type: Review

References (129)

1. Van de Werf F., Ardissino D., Betriu A., Cokkinos D.V., Falk E., Fox K.A., et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 24 (2003) 28-66
2. Braunwald E., and Kloner R.A. Myocardial reperfusion: a double-edged sword?. J Clin Invest 76 (1985) 1713-1719
3. Kloner R.A. Does reperfusion injury exist in humans?. J Am Coll Cardiol 21 (1993) 537-545
4. Jordan J.E., Zhao Z.Q., and Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 43 (1999) 860-878
5. Collard C.D., and Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology 94 (2001) 1133-1138
6. Matsumura K., Jeremy R.W., Schaper J., and Becker L.C. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 97 (1998) 795-804
7. Farb A., Kolodgie F.D., Jenkins M., and Virmani R. Myocardial infarct extension during reperfusion after coronary artery occlusion: pathologic evidence. J Am Coll Cardiol 21 (1993) 1245-1253
8. Frame L.H., Lopez J.A., Khaw B.A., Fallon J.T., Haber E., and Powell Jr. W.J. Early membrane damage during coronary reperfusion in dogs. Detection by radiolabeled anticardiac myosin (Fab')2. J Clin Invest 72 (1983) 535-544
9. Reffelmann T., and Kloner R.A. The "no-reflow" phenomenon: basic science and clinical correlates. Heart 87 (2002) 162-168
10. Engler R.L., Schmid-Schonbein G.W., and Pavelec R.S. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 111 (1983) 98-111
11. Kloner R.A., and Jennings R.B. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. Circulation 104 (2001) 2981-2989
12. Bolli R., Becker L., Gross G., Mentzer Jr. R., Balshaw D., and Lathrop D.A. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95 (2004) 125-134
13. Piper H.M., Garcia-Dorado D., and Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 38 (1998) 291-300
14. 2+ exchanger in reoxygenation-induced cardiomyocyte injury. Cardiovasc Res 51 (2001) 241-250
15. Hausenloy D.J., Duchen M.R., and Yellon D.M. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 60 (2003) 617-625
16. Cannon III R.O. Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2 (2005) 88-94
17. Piper H.M., Abdallah Y., and Schafer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 61 (2004) 365-371
18. 2+ exchanger at the time of myocardial reperfusion on hypercontracture and cell death. Cardiovasc Res 55 (2002) 739-748
19. Menown I.B., and Adgey A.A. Cardioprotective therapy and sodium-hydrogen exchange inhibition: current concepts and future goals. J Am Coll Cardiol 38 (2001) 1651-1653
20. Woods K.L. Possible pharmacological actions of magnesium in acute myocardial infarction. Br J Clin Pharmacol 32 (1991) 3-10
21. Garcia-Dorado D., Theroux P., Fernandez-Aviles F., Elizaga J., Solares J., and Galinanes M. Diltiazem and progression of myocardial ischemic damage during coronary artery occlusion and reperfusion in porcine hearts. J Am Coll Cardiol 10 (1987) 906-911
22. Higginson L., Tang A., Knoll G., and Calvin J. Effect of intracoronary diltiazem on infarct size and regional myocardial function in the ischemic reperfused canine heart. J Am Coll Cardiol 18 (1991) 868-875
23. Maulik M., Maulik S.K., and Kumari R. Importance of timing of magnesium administration: a study on the isolated ischemic-reperfused rat heart. Magnes Res 12 (1999) 37-42
24. Haigney M.C., Silver B., Tanglao E., Silverman H.S., Hill J.D., Shapiro E., et al. Noninvasive measurement of tissue magnesium and correlation with cardiac levels. Circulation 92 (1995) 2190-2197
25. Christensen C.W., Rieder M.A., Silverstein E.L., and Gencheff N.E. Magnesium sulfate reduces myocardial infarct size when administered before but not after coronary reperfusion in a canine model. Circulation 92 (1995) 2617-2621
26. Herzog W.R., Schlossberg M.L., MacMurdy K.S., Edenbaum L.R., Gerber M.J., Vogel R.A., et al. Timing of magnesium therapy affects experimental infarct size. Circulation 92 (1995) 2622-2626
27. The HINT Research Group. Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 56 (1986) 400-413
28. Theroux P., Gregoire J., Chin C., Pelletier G., de Guise P., and Juneau M. Intravenous diltiazem in acute myocardial infarction. DATA trial. J Am Coll Cardiol 32 (1998) 620-628
29. Pizzetti G., Mailhac A., Li Volsi L., Di Marco F., Lu C., Margonato A., et al. Beneficial effects of diltiazem during myocardial reperfusion: a randomized trial in acute myocardial infarction. Ital Heart J 2 (2001) 757-765
30. Sheiban I., Tonni S., Chizzoni A., Marini A., and Trevi G. Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine. Cardiovasc Drugs Ther 11 (1997) 5-16
31. Woods K.L., Fletcher S., Roffe C., and Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the LIMIT-2. Lancet 339 (1992) 1553-1558
32. ISIS-4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345 (1995) 669-685
33. Santoro G.M., Antoniucci D., Bolognese L., Valenti R., Buonamici P., Trapani M., et al. A randomized study of intravenous magnesium in acute myocardial infarction treated with direct coronary angioplasty. Am Heart J 140 (2000) 891-897
34. MAGIC. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the MAGIC Trial. Lancet 360 (2002) 1189-1196
35. + exchange: structure, regulation, and its role in heart disease. Circ Res 85 (1999) 777-786
36. + exchange inhibitor cariporide attenuates cell injury predominantly during ischemia and not at onset of reperfusion in porcine hearts with low residual blood flow. Circulation 102 (2000) 1977-1982
37. + exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation 101 (2000) 2902-2908
38. + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the ESCAMI trial. J Am Coll Cardiol 38 (2001) 1644-1650
39. Bar F.W., Tzivoni D., Dirksen M.T., Fernandez-Ortiz A., Heyndrickx G.R., Brachmann J., et al. Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the CASTEMI study. Eur Heart J 27 (2006) 2516-2523
40. Boyce S.W., Bartels C., Bolli R., Chaitman B., Chen J.C., Chi E., et al. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg 126 (2003) 420-427
41. + exchange inhibition by cariporide on death and nonfatal myocardial infarction in patients undergoing CABG: The Expedition Study. Late-Breaking Clinical Trial Abstracts. Circulation 108 (2003) 3M [Presentation on AHA]
42. Black S.C. In vivo models of myocardial ischemia and reperfusion injury: application to drug discovery and evaluation. J Pharmacol Toxicol Methods 43 (2000) 153-167
43. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 61 (2004) 481-497
44. Flaherty J.T., Pitt B., Gruber J.W., Heuser R.R., Rothbaum D.A., Burwell L.R., et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 89 (1994) 1982-1991
45. Tsujita K., Shimomura H., Kawano H., Hokamaki J., Fukuda M., Yamashita T., et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 94 (2004) 481-484
46. Wall T., Califf R., Blankenship J., Talley J., Tannenbaum M., Schwaiger M., et al. Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the TAMI-9 Trial. Circulation 90 (1994) 114-120
47. Schaer G.L., Spaccavento L.J., Browne K.F., Krueger K.A., Krichbaum D., Phelan J.M., et al. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial. Circulation 94 (1996) 298-2307
48. Collaborative Organization for RheothRx Evaluation (CORE). Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Circulation 96 (1997) 192-201
49. Baran K.W., Nguyen M., McKendall G.R., Lambrew C.T., Dykstra G., Palmeri S.T., et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: the LIMIT-AMI study. Circulation 104 (2001) 2778-2783
50. Rusnak J.M., Kopecky S.L., Clements I.P., Gibbons R.J., Holland A.E., Peterman H.S., et al. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (FESTIVAL study). Am J Cardiol 88 (2001) 482-487
51. Faxon D.P., Gibbons R.J., Chronos N.A., Gurbel P.A., and Sheehan F. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: results of the HALT-MI study. J Am Coll Cardiol 40 (2002) 1199-1204
52. Tanguay J.F., Krucoff M.W., Gibbons R.J., Chavez E., Liprandi A.S., Molina-Viamonte V., et al. Efficacy of a novel P-selectin antagonist, rPSGL-Ig for reperfusion therapy in acute myocardial infarction: the RAPSODY trial. J Am Coll Cardiol 108 (2003) 2387-2392
53. Dirksen M.T., Laarman G., van 't Hof A.W., Guagliumi G., Tonino W.A., Tavazzi L., et al. The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty. Safety and efficacy of a novel tetrapeptide, ITF-1697. The PARI-MI study. Eur Heart J 25 (2004) 392-400
54. Granger C.B., Mahaffey K.W., Weaver W.D., Theroux P., Hochman J.S., Filloon T.G., et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMMA trial. Circulation 108 (2003) 1184-1190
55. Mahaffey K.W., Granger C.B., Nicolau J.C., Ruzyllo W., Weaver W.D., Theroux P., et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPLY trial. Circulation 108 (2003) 1176-1183
56. Armstrong P.W., Granger C.B., Adams P.X., Hamm C., Holmes Jr. D., O'Neill W.W., et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention. JAMA 297 (2007) 43-51
57. Ely S.W., and Berne R.M. Protective effects of adenosine in myocardial ischemia. Circulation 85 (1992) 893-904
58. Olafsson B., Forman M.B., Puett D.W., Pou A., Cates C.U., Friesinger G.C., et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 76 (1987) 1135-1145
59. Vander Heide R.S., and Reimer K.A. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res 31 (1996) 711-718
60. Goto M., Miura T., Iliodoromitis E.K., O'Leary E.L., Ishimoto R., Yellon D.M., et al. Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species. Cardiovasc Res 25 (1991) 943-949
61. Homeister J.W., Hoff P.T., Fletcher D.D., and Lucchesi B.R. Combined adenosine and lidocaine administration limits myocardial reperfusion injury. Circulation 82 (1990) 595-608
62. Garratt K.N., Holmes Jr. D.R., Molina-Viamonte V., Reeder G.S., Hodge D.O., Bailey K.R., et al. Intravenous adenosine and lidocaine in patients with acute mycocardial infarction. Am Heart J 136 (1998) 196-204
63. Mahaffey K.W., Puma J.A., Barbagelata N.A., DiCarli M.F., Leesar M.A., Browne K.F., et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of the AMISTAD trial. J Am Coll Cardiol 34 (1999) 1711-1720
64. Ross A.M., Gibbons R.J., Stone G.W., Kloner R.A., and Alexander R.W. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45 (2005) 1775-1780
65. Kopecky S.L., Aviles R.J., Bell M.R., Lobl J.K., Tipping D., Frommell G., et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE study. Am Heart J 146 (2003) 146-152
66. Quintana M., Hjemdahl P., Sollevi A., Kahan T., Edner M., Rehnqvist N., et al. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis: the ATTACC study. Eur J Clin Pharmacol 59 (2003) 1-9
67. Marzilli M., Orsini E., Marraccini P., and Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 101 (2000) 2154-2159
68. Vinten-Johansen J., Zhao Z.Q., Corvera J.S., Morris C.D., Budde J.M., Thourani V.H., et al. Adenosine in myocardial protection in on-pump and off-pump cardiac surgery. Ann Thorac Surg 75 (2003) S691-S699
69. Sodi-Pallares D., Testelli M.R., Fishleder B.L., Bisteni A., Medrano G.A., Friedland C., et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol 9 (1962) 166-181
70. Bertuglia S., Giusti A., Fedele S., and Picano E. Glucose-insulin-potassium treatment in combination with dipyridamole inhibits ischaemia-reperfusion-induced damage. Diabetologia 44 (2001) 2165-2170
71. Diaz R., Paolasso E.A., Piegas L.S., Tajer C.D., Moreno M.G., Corvalan R., et al. Metabolic modulation of acute myocardial infarction. The ECLA Collaborative Group. Circulation 98 (1998) 2227-2234
72. Fath-Ordoubadi F., and Beatt K.J. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 96 (1997) 1152-1156
73. Taegtmeyer H., and de Villalobos D.H. Metabolic support for the postischaemic heart. Lancet 345 (1995) 1552-1555
74. Oliver M.F., and Opie L.H. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 343 (1994) 155-158
75. Jonassen A.K., Sack M.N., Mjos O.D., and Yellon D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89 (2001) 1191-1198
76. Jonassen A.K., Aasum E., Riemersma R.A., Mjos O.D., and Larsen T.S. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 14 (2000) 615-623
77. Eberli F.R., Weinberg E.O., Grice W.N., Horowitz G.L., and Apstein C.S. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res 68 (1991) 466-481
78. Sybers H.D., Maroko P.R., Ashraf M., Libby P., and Braunwald E. The effect of glucose-insulin-potassium on cardiac ultrastructure following acute experimental coronary occlusion. Am J Pathol 70 (1973) 401-420
79. Mehta S.R., Yusuf S., Diaz R., Zhu J., Pais P., Xavier D., et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA trial. JAMA 293 (2005) 437-446
80. Ceremuzynski L., Budaj A., Czepiel A., Burzykowski T., Achremczyk P., Smielak-Korombel W., et al. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of the Pol-GIK trial. Cardiovasc Drugs Ther 13 (1999) 191-200
81. van der Horst I.C., Zijlstra F., van't Hof A.W., Doggen C.J., de Boer M.J., Suryapranata H., et al. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the GIPS. J Am Coll Cardiol 42 (2003) 784-791
82. Timmer J.R., Svilaas T., Ottervanger J.P., Henriques J.P., Dambrink J.H., van den Broek S.A., et al. Glucose-insulin-potassium infusion in patients with acute myocardial infarction without signs of heart failure: the GIPS-II. J Am Coll Cardiol 47 (2006) 1730-1731
83. Pache J., Kastrati A., Mehilli J., Bollwein H., Ndrepepa G., Schuhlen H., et al. A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. Am Heart J 148 (2004) e3
84. Hearse D.J., Stewart D.A., and Braimbridge M.V. Myocardial protection during ischemic cardiac arrest. Possible deleterious effects of glucose and mannitol in coronary infusates. J Thorac Cardiovasc Surg 76 (1978) 16-23
85. Doenst T., Bothe W., and Beyersdorf F. Therapy with insulin in cardiac surgery: controversies and possible solutions. Ann Thorac Surg 75 (2003) S721-S728
86. The EMIP-FR Group. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy. Eur Heart J 21 (2000) 1537-1546
87. Kurz T., Schafer U., Dendorfer A., Hartmann F., Raasch W., Tolg R., et al. Effects of intracoronary low-dose enalaprilat as an adjunct to primary percutaneous transluminal coronary angiography in acute myocardial infarction. Am J Cardiol 88 (2001) 1351-1357
88. Sakata Y., Kodama K., Komamura K., Lim Y.-J., Ishikura F., Hirayama A., et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am Heart J 133 (1997) 616-621
89. Ito H., Taniyama Y., Iwakura K., Nishikawa N., Masuyama T., Kuzuya T., et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 33 (1999) 654-660
90. Ono H., Osanai T., Ishizaka H., Hanada H., Kamada T., Onodera H., et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J 148 (2004) E15
91. Acar C., Partington M.T., and Buckberg G.D. Studies of controlled reperfusion after ischemia. XVII. Reperfusion conditions: controlled reperfusion through an internal mammary artery graft-a new technique emphasizing fixed pressure versus fixed flow. J Thorac Cardiovasc Surg 100 (1990) 724-736
92. Zhao Z.Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.P., Guyton R.A., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol 285 (2003) H579-H588
93. Tsang A., Hausenloy D.J., Mocanu M.M., and Yellon D.M. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95 (2004) 230-232
94. Yang X.M., Proctor J.B., Cui L., Krieg T., Downey J.M., and Cohen M.V. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44 (2004) 1103-1110
95. Staat P., Rioufol G., Piot C., Cottin Y., Cung T.T., L'Huillier I., et al. Postconditioning the human heart. Circulation 112 (2005) 2143-2148
96. Wang Q.D., Pernow J., Sjoquist P.O., and Ryden L. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res 55 (2002) 25-37
97. Galinanes M., and Fowler A.G. Role of clinical pathologies in myocardial injury following ischaemia and reperfusion. Cardiovasc Res 61 (2004) 512-521
98. Ito B.R. Gradual onset of myocardial ischemia results in reduced myocardial infarction. Association with reduced contractile function and metabolic downregulation. Circulation 91 (1995) 2058-2070
99. Liem D.A., te Lintel Hekkert M., Manintveld O.C., Boomsma F., Verdouw P.D., and Duncker D.J. Myocardium tolerant to an adenosine-dependent ischemic preconditioning stimulus can still be protected by stimuli that employ alternative signaling pathways. Am J Physiol 288 (2005) H1165-H1172
100. Coller B.S. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J 138 (1999) S1-S5
101. Kastrati A., Mehilli J., Dirschinger J., Schricke U., Neverve J., Pache J., et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction. Lancet 359 (2002) 920-925
102. Woods K.L., and Abrams K. The importance of effect mechanism in the design and interpretation of clinical trials: the role of magnesium in acute myocardial infarction. Prog Cardiovasc Dis 44 (2002) 267-274
103. Kizer J.R., Cannon C.P., McCabe C.H., Mueller H.S., Schweiger M.J., Davis V.G., et al. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Am Heart J 137 (1999) 79-92
104. Tiefenbacher C.P., Kapitza J., Dietz V., Lee C.H., and Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am J Physiol 285 (2003) H59-H64
105. Christian T.F., Schwartz R.S., and Gibbons R.J. Determinants of infarct size in reperfusion therapy for acute myocardial infarction. Circulation 86 (1992) 81-90
106. Reimer K.A., Jennings R.B., Cobb F.R., Murdock R.H., Greenfield Jr. J.C., Becker L.C., et al. Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Circ Res 56 (1985) 651-665
107. Elsman P., van 't Hof A.W., de Boer M.J., Hoorntje J.C., Suryapranata H., Dambrink J.H., et al. Role of collateral circulation in the acute phase of ST-segment-elevation myocardial infarction treated with primary coronary intervention. Eur Heart J 25 (2004) 854-858
108. Sabia P.J., Powers E.R., Ragosta M., Sarembock I.J., Burwell L.R., and Kaul S. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 327 (1992) 1825-1831
109. Kloner R.A., Forman M.B., Gibbons R.J., Ross A.M., Alexander R.W., and Stone G.W. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 27 (2006) 2400-2405
110. Bassand J.P., Danchin N., Filippatos G., Gitt A., Hamm C., Silber S., et al. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J 26 (2005) 2733-2741
111. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI). Lancet 367 (2006) 569-578
112. Vinten-Johansen J., Zhao Z.Q., Zatta A.J., Kin H., Halkos M.E., and Kerendi F. Postconditioning: a new link in nature's armor against myocardial ischemia-reperfusion injury. Basic Res Cardiol (2005)
113. Topol E.J., and Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101 (2000) 570-580
114. Tanaka A., Kawarabayashi T., Nishibori Y., Sano T., Nishida Y., Fukuda D., et al. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation 105 (2002) 2148-2152
115. Henriques J.P., Zijlstra F., Ottervanger J.P., de Boer M.J., van 't Hof A.W., Hoorntje J.C., et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 23 (2002) 1112-1117
116. Ito H., Maruyama A., Iwakura K., Takiuchi S., Masuyama T., Hori M., et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 93 (1996) 223-228
117. Jordan Jr. W.D., Voellinger D.C., Doblar D.D., Plyushcheva N.P., Fisher W.S., and McDowell H.A. Microemboli detected by transcranial Doppler monitoring in patients during carotid angioplasty versus carotid endarterectomy. Cardiovasc Surg 7 (1999) 33-38
118. Piana R.N., Paik G.Y., Moscucci M., Cohen D.J., Gibson C.M., Kugelmass A.D., et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 89 (1994) 2514-2518
119. Stone G.W., Webb J., Cox D.A., Brodie B.R., Qureshi M., Kalynych A., et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. JAMA 293 (2005) 1063-1072
120. Gick M., Jander N., Bestehorn H.P., Kienzle R.P., Ferenc M., Werner K., et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 112 (2005) 1462-1469
121. Kloner R.A., and Rezkalla S.H. Cardiac protection during acute myocardial infarction: where do we stand in 2004?. J Am Coll Cardiol 44 (2004) 276-286
122. Verrier E.D., Shernan S.K., Taylor K.M., Van de Werf F., Newman M.F., Chen J.C., et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass. JAMA 291 (2004) 2319-2327
123. + exchange inhibitor reduces infarct size in pigs. Cardiovasc Res 30 (1995) 945-951
124. Linz W., Albus U., Crause P., Jung W., Weichert A., Scholkens B.A., et al. Dose-dependent reduction of myocardial infarct mass in rabbits by the NHE-1 inhibitor cariporide (HOE 642). Clin Exp Hypertens 20 (1998) 733-749
125. Gumina R.J., Mizumura T., Beier N., Schelling P., Schultz J.J., and Gross G.J. A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion. J Pharmacol Exp Ther 286 (1998) 175-183
126. Theroux P., Chaitman B.R., Danchin N., Erhardt L., Meinertz T., Schroeder J.S., et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Results of the GUARDIAN trial. Circulation 102 (2000) 3032-3038
127. Gibbons R.J., Valeti U.S., Araoz P.A., and Jaffe A.S. The quantification of infarct size. J Am Coll Cardiol 44 (2004) 1533-1542
128. Boersma E., Mercado N., Poldermans D., Gardien M., Vos J., and Simoons M.L. Acute myocardial infarction. Lancet 361 (2003) 847-858
129. Yellon D.M., and Baxter G.F. Sodium-hydrogen exchange in myocardial reperfusion injury. Lancet 356 (2000) 522-523